MiR-145 Overexpression Triggers Alteration of the Whole Transcriptome and Inhibits Breast Cancer Development
Overview
General Medicine
Pharmacology
Affiliations
Cumulative evidence has associated microRNA (miRNA) with cancer development, and among those miRNAs, miR-145 has been identified as an anti-oncomiRNA. However, the comprehensive mechanisms of action of miR-145 in breast cancer development have not yet been fully elucidated. Herein, we performed next-generation sequencing to detect the expression profiles of the transcriptome and conducted cellular function experiments after miR-145 overexpression. The results verified the inhibitory effects of miR-145 on breast cancer cell proliferation, colony formation, migration and invasion. Sequencing data revealed that miR-145 triggered the alteration of the whole transcriptome and further led to regulation of the competing endogenous RNA (ceRNA) network. Our study also identified a list of 49 target mRNAs of miR-145 and specific non-coding RNAs, which could be utilized as potential breast cancer biomarkers. This study might serve as a significant platform for further research on miR-145 along with the ceRNA network in breast cancer.
Abtin M, Nafisi N, Hosseinzadeh A, Kadkhoda S, Omranipour R, Sahebi L Noncoding RNA Res. 2024; 9(2):367-375.
PMID: 38511058 PMC: 10950563. DOI: 10.1016/j.ncrna.2024.01.016.
Alipour S, Khalighfard S, Khori V, Amiriani T, Tajaldini M, Dehghan M Sci Rep. 2022; 12(1):12054.
PMID: 35835840 PMC: 9283473. DOI: 10.1038/s41598-022-16398-7.
Zhou Y, Cai W, Lu H Bioengineered. 2022; 13(4):11310-11320.
PMID: 35499128 PMC: 9278436. DOI: 10.1080/21655979.2022.2068756.
Non-Exosomal and Exosome-Derived miRNAs as Promising Biomarkers in Canine Mammary Cancer.
Petrouskova P, Hudakova N, Maloveska M, Humenik F, Cizkova D Life (Basel). 2022; 12(4).
PMID: 35455015 PMC: 9032658. DOI: 10.3390/life12040524.
An integrated bioinformatics analysis to investigate the targets of miR-133a-1 in breast cancer.
Meng Y, Tang H, Luo Z, Tan W, Chen L, Du Y Transl Cancer Res. 2022; 10(3):1238-1248.
PMID: 35116451 PMC: 8799015. DOI: 10.21037/tcr-20-2681.